These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
162 related items for PubMed ID: 574066
1. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE. Circulation; 1979 Dec; 60(6):1201-7. PubMed ID: 574066 [Abstract] [Full Text] [Related]
2. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. Spicer RL, Rocchini AP, Crowley DC, Vasiliades J, Rosenthal A. Circulation; 1983 Feb; 67(2):413-20. PubMed ID: 6681534 [Abstract] [Full Text] [Related]
3. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Rosing DR, Idänpään-Heikkilä U, Maron BJ, Bonow RO, Epstein SE. Am J Cardiol; 1985 Jan 25; 55(3):185B-195B. PubMed ID: 3881913 [Abstract] [Full Text] [Related]
4. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. Betocchi S, Piscione F, Losi M A, Pace L, Boccalatte M, Perrone-Filardi P, Cappelli-Bigazzi, Briguori C, Manganelli F, Ciampi Q, Salvatore M, Chiariello M. Am J Cardiol; 1996 Aug 15; 78(4):451-7. PubMed ID: 8752192 [Abstract] [Full Text] [Related]
5. Verapamil therapy: a new approach to pharmacologic treatment of hypertrophic cardiomyopathy. Rosing DR, Kent KM, Maron BJ, Condit J, Epstein SE. Chest; 1980 Jul 15; 78(1 Suppl):239-47. PubMed ID: 6995039 [Abstract] [Full Text] [Related]
6. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. Bonow RO, Ostrow HG, Rosing DR, Cannon RO, Lipson LC, Maron BJ, Kent KM, Bacharach SL, Green MV. Circulation; 1983 Nov 15; 68(5):1062-73. PubMed ID: 6684510 [Abstract] [Full Text] [Related]
7. Effects of short-term administration of verapamil on left ventricular relaxation and filling dynamics measured by a combined hemodynamic-ultrasonic technique in patients with hypertrophic cardiomyopathy. TenCate FJ, Serruys PW, Mey S, Roelandt J. Circulation; 1983 Dec 15; 68(6):1274-9. PubMed ID: 6685582 [Abstract] [Full Text] [Related]
8. Influence of verapamil therapy on left ventricular performance at rest and during exercise in hypertrophic cardiomyopathy. Hanrath P, Schlüter M, Sonntag F, Diemert J, Bleifeld W. Am J Cardiol; 1983 Sep 01; 52(5):544-8. PubMed ID: 6684388 [Abstract] [Full Text] [Related]
9. Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. Anderson DM, Raff GL, Ports TA, Brundage BH, Parmley WW, Chatterjee K. Br Heart J; 1984 May 01; 51(5):523-9. PubMed ID: 6539120 [Abstract] [Full Text] [Related]
10. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Pollick C, Kimball B, Henderson M, Wigle ED. Am J Cardiol; 1988 Dec 01; 62(17):1248-51. PubMed ID: 3195486 [Abstract] [Full Text] [Related]
11. Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. Stenson RE, Flamm MD, Harrison DC, Hancock EW. Am J Cardiol; 1973 Jun 01; 31(6):763-73. PubMed ID: 4735938 [No Abstract] [Full Text] [Related]
12. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Cannon RO, Rosing DR, Maron BJ, Leon MB, Bonow RO, Watson RM, Epstein SE. Circulation; 1985 Feb 01; 71(2):234-43. PubMed ID: 4038383 [Abstract] [Full Text] [Related]
14. The hemodynamic effects of intravenous verapamil in patients on chronic propranolol therapy. Reddy PS, Uretsky BF, Steinfeld M. Am Heart J; 1984 Jan 01; 107(1):97-101. PubMed ID: 6691247 [Abstract] [Full Text] [Related]
15. Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy. Hongo M, Nakatsuka T, Takenaka H, Tanaka M, Watanabe N, Yazaki Y, Sekiguchi M. Cardiology; 1996 Jan 01; 87(1):6-11. PubMed ID: 8631046 [Abstract] [Full Text] [Related]
16. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. Wilmshurst PT, Thompson DS, Juul SM, Jenkins BS, Webb-Peploe MM. Br Heart J; 1986 Dec 01; 56(6):544-53. PubMed ID: 3801246 [Abstract] [Full Text] [Related]
17. Left ventricular end-diastolic pressure-volume relationships in hypertrophic cardiomyopathy. Changes induced by verapamil. Tendera M, Polonski L, Kozielska E. Chest; 1983 Jul 01; 84(1):54-7. PubMed ID: 6683147 [Abstract] [Full Text] [Related]
18. Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy. Kyriakidis M, Triposkiadis F, Dernellis J, Androulakis AE, Mellas P, Kelepeshis GA, Gialafos JE. Circulation; 1998 Apr 14; 97(14):1342-7. PubMed ID: 9577944 [Abstract] [Full Text] [Related]
19. The acute and chronic effects of verapamil on left ventricular function in patients with hypertrophic cardiomyopathy. Bonow RO, Rosing DR, Epstein SE. Eur Heart J; 1983 Nov 14; 4 Suppl F():57-65. PubMed ID: 6686545 [Abstract] [Full Text] [Related]
20. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. Rosing DR, Kent KM, Maron BJ, Condit J, Epstein SE. Clin Invest Med; 1980 Nov 14; 3(1-2):195-203. PubMed ID: 7009000 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]